Holen Sie sich die Stockscreener-App
14.62
3.39%
0.48
Handel nachbörslich:
14.67
0.05
+0.34%
Schlusskurs vom Vortag:
$14.14
Offen:
$14.175
24-Stunden-Volumen:
38,741
Relative Volume:
0.78
Marktkapitalisierung:
$609.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.28M
KGV:
-10.30
EPS:
-1.42
Netto-Cashflow:
$-57.45M
1W Leistung:
-8.57%
1M Leistung:
+4.21%
6M Leistung:
+22.09%
1J Leistung:
+50.57%
1-Tages-Spanne:
$14.18
$14.88
1-Wochen-Bereich:
$14.00
$15.76
52-Wochen-Spanne:
$9.60
$18.00
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| OCS | 14.62 | 609.48M | 0 | -75.28M | -57.45M | -1.42 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Reports Q3 2024 Financial Progress - TipRanks
Oculis Holding’s Financial Struggles Amid Asset Growth - TipRanks
Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewswire
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins - GlobeNewswire Inc.
Oculis (OCS) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Oculis (NASDAQ:OCS) Hits New 12-Month HighWhat's Next? - MarketBeat
Oculis: Lack Of Coverage Only Real Risk For This Solid Company - Seeking Alpha
abrdn plc Sells 279,879 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat
Oculis (NASDAQ:OCS) Sees Strong Trading VolumeHere's Why - MarketBeat
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - MSN
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39% - Yahoo Finance
Oculis (NASDAQ:OCS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 133.7% - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Oculis (NASDAQ:OCS) Shares Gap DownHere's Why - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Oculis (NASDAQ:OCS) - MarketBeat
Financial Comparison: Oculis (NASDAQ:OCS) and Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Oculis (NASDAQ:OCS) Reaches New 52-Week HighTime to Buy? - MarketBeat
Oculis Holding AG's (NASDAQ:OCS) market cap touched US$586m last week, benefiting both individual investors who own 55% as well as institutions - Simply Wall St
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials - TipRanks
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - StockTitan
Oculis (NASDAQ:OCS) Trading Up 4.8%Here's What Happened - MarketBeat
Oculis Accelerates Enrollment in both DIAMOND Phase 3 - GlobeNewswire
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema - GlobeNewswire
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - StockTitan
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
Oculis (NASDAQ:OCS) Hits New 52-Week High – Here’s What Happened - Defense World
Oculis (NASDAQ:OCS) Hits New 52-Week HighWhat's Next? - MarketBeat
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Objective long/short (OCS) Report - Stock Traders Daily
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer - Vision Monday
Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Reviewing Oculis (NASDAQ:OCS) & Journey Medical (NASDAQ:DERM) - Defense World
Learn to Evaluate (OCS) using the Charts - Stock Traders Daily
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):